Talking with the North Carolina Harm Reduction Coalition’s Loftin Wilson about the coalition’s work, how the opioid epidemic ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Celebrating the stories of PATF and Allies FEATURING: Kathi Boyle, Stuart Fisk, Tammy Frech, DJ Stemmler & Pam Vingle, Nachum Golan & Steve Hough, Alan Jones, ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Burlington Free Press on MSN
UVM joins major study on drug use and treatment barriers across New England
A new study aims to better understand drug-use trends and barriers to health care in Vermont and New England. The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback